Disfunción eréctil y YouTube: calidad de los vídeos en español / Erectile dysfunction and YouTube: Quality of videos in Spanish

Introducción: La disfunción eréctil (DE) es una de las enfermedades urológicas más prevalentes, pero los datos de la calidad de su información en redes sociales son escasos. El objetivo de nuestro estudio fue evaluar la calidad de la información sobre DE contenida en los vídeos de YouTube. Material y métodos: Estudio descriptivo transversal de los 50 primeros vídeos en castellano publicados en YouTube, evaluados por tres urólogos mediante dos cuestionarios validados: Patient Education Materials Assessment Tool (PEMAT) y DISCERN, clasificándolos según puntuación DISCERN en calidad pobre y moderada-buena. Resultados: La mediana de duración fue de 2,42 minutos, y la de visualizaciones, de 94.197 (2.313-3.027.890), con 682,5 (0-54.020) «me gusta» y 39 (0-2.843) «no me gusta». La mediana de PEMAT fue del 29% en inteligibilidad y del 29% en factibilidad. Con DISCERN, 27 vídeos (57,4%) fueron de calidad pobre y 20 (42,6%), de calidad moderada-buena. No observamos diferencias significativas entre ambos grupos en duración, visualizaciones, número de «me gusta» o de «no me gusta». Sí existieron diferencias en PEMAT de inteligibilidad y de factibilidad. El 86,7% de los protagonizados por personal médico fueron de calidad moderada-buena (p=0,001). El 85,7% de los que describían el tratamiento fueron de calidad moderada-buena y el 84% de los vídeos no médicos fueron de calidad pobre (p=0,001). Conclusiones: La mayoría de los vídeos sobre DE en YouTube son de calidad pobre. Los vídeos de mayor calidad son aquellos realizados por profesionales, aunque no son los más vistos. Sería importante el desarrollo de medidas para evitar la difusión de desinformación entre los usuarios de redes sociales. (AU)

Introduction: Erectile dysfunction (ED) is one of the most prevalent urological diseases, but there is limited data about the quality of its information in social networks. The aim of our study was to assess the quality of ED information contained in YouTube videos. Material and methods: Descriptive study of the first 50 Spanish-language videos, published on YouTube, evaluated by three urologists. We used two validated questionnaires: PEMAT (Patient Education Materials Assessment Tool) and DISCERN. Videos were classified according to DISCERN score into poor or moderate-good quality. Results: The median time duration was 2.42minutes (0.15-3.58), 94,197 views (2,313-3,027,890), 682.5 «likes» (0-54,020) and 39 «dislikes» (0-2843). The median of PEMAT score was 29% (9%-95.5%) in understandability and 29% (0-95.5%) in actionability. According to DISCERN score 27 videos (57.4%) had poor quality and 20 (42.6%) moderate-good quality. There were no significant differences between the two groups in time duration, views, «likes» or «dislikes». There were differences in PEMAT score in understandability and actionability. The 86.7% of the moderate-good quality videos were starred by health care provider (P=.001). Also, the 85.7% of videos that describes treatment had moderate-good quality (P=.001). The 84% of the non-medical videos had a poor quality (P=.001). Conclusion: Most ED videos on YouTube have poor quality. The highest quality videos are those made by professionals, although they are not the most viewed. It would be important to develop measures to prevent the spread of misinformation among social network users. (AU)

[Erectile dysfunction and YouTube: Quality of videos in Spanish]. / Disfunción eréctil y YouTube: calidad de los vídeos en español.

INTRODUCTION: Erectile dysfunction (ED) is one of the most prevalent urological diseases, but there is limited data about the quality of its information in social networks. The aim of our study was to assess the quality of ED information contained in YouTube videos. MATERIAL AND METHODS: Descriptive study of the first 50 Spanish-language videos, published on YouTube, evaluated by three urologists. We used two validated questionnaires: PEMAT (Patient Education Materials Assessment Tool) and DISCERN. Videos were classified according to DISCERN score into poor or moderate-good quality. RESULTS: The median time duration was 2.42minutes (0.15-3.58), 94,197 views (2,313-3,027,890), 682.5 «likes¼ (0-54,020) and 39 «dislikes¼ (0-2843). The median of PEMAT score was 29% (9%-95.5%) in understandability and 29% (0-95.5%) in actionability. According to DISCERN score 27 videos (57.4%) had poor quality and 20 (42.6%) moderate-good quality. There were no significant differences between the two groups in time duration, views, «likes¼ or «dislikes¼. There were differences in PEMAT score in understandability and actionability. The 86.7% of the moderate-good quality videos were starred by health care provider (P=.001). Also, the 85.7% of videos that describes treatment had moderate-good quality (P=.001). The 84% of the non-medical videos had a poor quality (P=.001). CONCLUSION: Most ED videos on YouTube have poor quality. The highest quality videos are those made by professionals, although they are not the most viewed. It would be important to develop measures to prevent the spread of misinformation among social network users.

Quality of bladder cancer information on YouTube.

Introduction: YouTube is one of the social networks most widely used as a source of information. However, there are doubts about the scientific quality of the information available. This study aims to characterise this by analysing videos about bladder cancer posted on YouTube. Material and methods: This was a cross-sectional descriptive study of the first 50 Spanish-language videos published on YouTube, leaving 38 for analysis. The videos were evaluated by three urologists using two validated questionnaires: Patient Education Materials Assessment Tool (PEMAT) and DISCERN (quality criteria for consumer health information), classifying them according to the score of the latter, in poor quality (1-2 points) and moderate/good quality (3-5 points). Results: The median PEMAT score was 71.6% (16-5-100%) for understanding and 35.5% (0-100%) for action. According to DISCERN, 26 videos (66.7%) were of poor quality and 12 (30.8%) of moderate/good quality. We found significant differences in terms of PEMAT of understanding (p = 0.004) and action (p = 0.000). In total, 90.9% of those involving medical staff were of low quality, which is paradoxical, but statistically significant (p = 0.01). Furthermore, 52.4% of those describing relevant information were of moderate/good quality, and 94.1% of those not describing relevant information were of poor quality (p = 0.02). Conclusions: More than 60% of the videos published on YouTube about bladder cancer in Spanish are of low quality. This represents an important risk of misinformation for the general public to whom most of them are addressed.

[Effectiveness and safety of intravesical hyaluronic acid for symptom control in chronic bladder diseases.] / Efectividad y seguridad del ácido hialurónico intravesical para el control de los síntomas en cistopatías crónicas.

INTRODUCTION: Chronic bladder disorders are a common condition. Endovesical hyaluronic acid is one of the therapeutic options for these patients. It is intended to verify the effectiveness and safety of treatment with intravesical instillations of hyaluronic acidin patients with bladder symptoms. MATERIAL AND METHODS: We present a series of 32 patients who received intravesical instillations of hyaluronic acid. Demographic characteristics, tolerance, and complications were analyzed, and symptoms before and after treatment were compared. Symptomatic relief achieved with treatment was assessed using the Patient Global Improvement Impression Scale (PGI-I). RESULTS: The median age was 74 years (IQR 60-78) and 65.6% were women. Median follow-up was 10 months (IQR 7-14). Eleven patients were diagnosed with radiotherapy-induced cystitis, 17 with bladder pain syndrome/interstitial cystitis (BPS/IC), and 4 with recurrent cystitis. After treatment, symptoms improved in 81.8% of patients with radical cystitis, 82.3% of patients with BPS/IC, and 75% of the patients with recurrent cystitis. The incidence of hematuria was reduced from 46.9% to 9.4% (p<0.001), filing symptoms from 62.5% to 12.5% (p<0.001) and pain from 40.6% to 12.5% (p= 0.004). 100% of the patients tolerated the treatment well and only 2 adverse effects were recorded (urinary tract infection and acute urine retention). During follow-up, 65.6% showed total control of symptoms and 15.6% partial control, achieving a greater response in the group of patients with hematuria (73.3%). 61.3% of the patients perceived relief of symptoms after treatment according to the PGI-I scale. 88.9% maintained symptomatic improvement at the end of the follow-up. CONCLUSION: Intravesical hyaluronic acid is a safe and effective treatment for filling symptoms, hematuria, and pain in patients with chronic cystopathies. Patients with radiotherapy-induced cystitis seem to especially benefit from treatment.

INTRODUCCIÓN: Las cistopatías crónicas son una patología frecuente. El ácido hialurónico endovesical es una de las opciones terapéuticas para estos pacientes. Se pretende verificar la efectividad y seguridad del tratamiento con instilaciones intravesicales de ácido hialurónico en pacientes con síntomas vesicales.MATERIAL Y MÉTODOS: Se presenta una serie de 32 pacientes que recibieron instilaciones intravesicales de ácido hialurónico. Se analizaron las características demográficas, tolerancia y complicaciones, y se compararon los síntomas antes y después del tratamiento. El alivio sintomático conseguido con el tratamiento se evaluó mediante la escala de impresión de mejoría global del paciente (PGI-I).RESULTADOS: La mediana de edad fue de 74 años (IQR60-78), siendo el 65,6% mujeres. La mediana de seguimiento fue 10 meses (IQR 7-14). Once pacientes fueron diagnosticados de cistitis rádica, 17 de síndrome de dolor vesical/cistitis intersticial (SDV/CI) y 4 de cistitis de repetición. Tras el tratamiento mejoraron los síntomas el 81,8% de los pacientes con cistitis rádica, el 82,3% de los pacientes con SDV/CI y el 75% de los pacientes con cistitis recurrentes. La incidencia de hematuria se redujo del 46,9% al 9,4% (p<0,001), los síntomas de llenado del 62,5% al 12,5% (p<0,001) y el dolor de un 40,6% al 12,5% (p=0,004). El 100% de los pacientes toleró bien el tratamiento y sólo se registraron 2 efectos adversos (infección del tracto urinario y retención agudade orina). Durante el seguimiento un 65,6% mostró un control total de los síntomas y un 15,6% un control parcial, consiguiendo una respuesta mayor en el grupo de pacientes con hematuria (73,3%). El 61,3% de los pacientes percibió alivio de los síntomas tras el tratamiento según la escala PGI-I. El 88,9% mantiene la mejoría de los síntomas al finalizar el seguimiento.CONCLUSIÓN: El ácido hialurónico intravesical es un tratamiento seguro y efectivo para los síntomas de llenado, hematuria y dolor en pacientes con cistopatías crónicas. Los pacientes con cistitis rádica parecen beneficiarse especialmente del tratamiento.

Efectividad y seguridad del ácido hialurónico intravesical para el control de los síntomas en cistopatías crónicas / Effectiveness and safety of intravesical hyaluronic acid for symptom control in chronic cystopathies

Introducción: Las cistopatías crónicas son una patología frecuente. El ácido hialurónicoendovesical es una de las opciones terapéuticas paraestos pacientes. Se pretende verificar la efectividad yseguridad del tratamiento con instilaciones intravesicales de ácido hialurónico en pacientes con síntomas vesicalesMaterial y métodos: Se presenta una serie de 32pacientes que recibieron instilaciones intravesicales deácido hialurónico. Se analizaron las características demográficas, tolerancia y complicaciones, y se compararon los síntomas antes y después del tratamiento. El alivio sintomático conseguido con el tratamiento se evaluómediante la escala de impresión de mejoría global delpaciente (PGI-I). Resultados: La mediana de edad fue de 74 años (IQR60-78), siendo el 65,6% mujeres. La mediana de seguimiento fue 10 meses (IQR 7-14). Once pacientes fuerondiagnosticados de cistitis rádica, 17 de síndrome dedolor vesical/cistitis intersticial (SDV/CI) y 4 de cistitisde repetición. Tras el tratamiento mejoraron los síntomasel 81,8% de los pacientes con cistitis rádica, el 82,3%de los pacientes con SDV/CI y el 75% de los pacientescon cistitis recurrentes. La incidencia de hematuria seredujo del 46,9% al 9,4% (p<0,001), los síntomas dellenado del 62,5% al 12,5% (p<0001), y el dolor de un40,6% al 12,5% (p=0,004). El 100% de los pacientestoleró bien el tratamiento y sólo se registraron 2 efectosadversos (infección del tracto urinario y retención agudade orina). Durante el seguimiento un 65,6% mostró uncontrol total de los síntomas y un 15,6% un control parcial, consiguiendo una respuesta mayor en el grupo depacientes con hematuria (73,3%). El 61,3% de los pacientes percibió alivio de los síntomas tras el tratamientosegún la escala PGI-I. El 88,9% mantiene la mejoría delos síntomas al finalizar el seguimiento.Conclusión: El ácido hialurónico intravesical es untratamiento seguro y efectivo para los síntomas de llenado, hematuria y...(AU)

Introduction: Chronic bladder disorders are a common condition. Endovesical hyaluronicacid is one of the therapeutic options for these patients.It is intended to verify the effectiveness and safety oftreatment with intravesical instillations of hyaluronic acidin patients with bladder symptoms. Material and methods: We present a series of 32patients who received intravesical instillations of hyaluronic acid. Demographic characteristics, tolerance,and complications were analyzed, and symptoms before and after treatment were compared. Symptomaticrelief achieved with treatment was assessed using thePatient Global Improvement Impression Scale (PGI-I).Results: The median age was 74 years (IQR 60-78)and 65.6% were women. Median follow-up was 10months (IQR 7-14). Eleven patients were diagnosed withradiotherapy-induced cystitis, 17 with bladder pain syndrome/interstitial cystitis (BPS/IC), and 4 with recurrentcystitis. After treatment, symptoms improved in 81.8%of patients with radical cystitis, 82.3% of patients withBPS/IC, and 75% of the patients with recurrent cystitis.The incidence of hematuria was reduced from 46.9% to9.4% (p<0.001), filling symptoms from 62.5% to 12.5%(p<0.001), and pain from 40.6% to 12.5% (p=0.004).100% of the patients tolerated the treatment well andonly 2 adverse effects were recorded (urinary tract infection and acute urine retention). During follow-up, 65.6%showed total control of symptoms and 15.6% partialcontrol, achieving a greater response in the group ofpatients with hematuria (73.3%). 61.3% of the patientsperceived relief of symptoms after treatment accordingto the PGI-I scale. 88.9% maintained symptomatic improvement at the end of the follow-up.Conclusion: Intravesical hyaluronic acid is a safeand effective treatment for filling symptoms, hematuria,and pain in patients with chronic cystopathies. Patientswith radiotherapy-induced cystitis seem to especiallybenefit from treatment.